- Home
- ARW vs IONS Comparison
ARW vs IONS Comparison
Compare ARW & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARW
- IONS
- Stock Information
- Founded
- ARW 1935
- IONS 1989
- Country
- ARW United States
- IONS United States
- Employees
- ARW N/A
- IONS N/A
- Industry
- ARW Electronic Components
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ARW Technology
- IONS Health Care
- Exchange
- ARW Nasdaq
- IONS Nasdaq
- Market Cap
- ARW 5.3B
- IONS 4.6B
- IPO Year
- ARW N/A
- IONS 1991
- Fundamental
- Price
- ARW $109.62
- IONS $30.82
- Analyst Decision
- ARW Hold
- IONS Buy
- Analyst Count
- ARW 4
- IONS 18
- Target Price
- ARW $121.25
- IONS $57.00
- AVG Volume (30 Days)
- ARW 742.2K
- IONS 1.9M
- Earning Date
- ARW 05-01-2025
- IONS 04-30-2025
- Dividend Yield
- ARW N/A
- IONS N/A
- EPS Growth
- ARW N/A
- IONS N/A
- EPS
- ARW 7.29
- IONS N/A
- Revenue
- ARW $27,923,324,000.00
- IONS $705,138,000.00
- Revenue This Year
- ARW $0.02
- IONS N/A
- Revenue Next Year
- ARW $8.06
- IONS $25.80
- P/E Ratio
- ARW $15.30
- IONS N/A
- Revenue Growth
- ARW N/A
- IONS N/A
- 52 Week Low
- ARW $86.50
- IONS $23.95
- 52 Week High
- ARW $137.80
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- ARW 54.94
- IONS 55.27
- Support Level
- ARW $99.11
- IONS $29.42
- Resistance Level
- ARW $113.79
- IONS $30.12
- Average True Range (ATR)
- ARW 2.74
- IONS 1.12
- MACD
- ARW 1.39
- IONS 0.40
- Stochastic Oscillator
- ARW 70.18
- IONS 76.23
About ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.